Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will ...

Bubendorfer-Vorwerk H, Schuster A, Lewis P, Picker N, Finger R (eds.): Prevalence of geographic atrophy in Germany—an assessment derived from literature-based estimates and claims data results.

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Geographic atrophy (GA) progressed more often in patients with better baseline vision and those with lesions closer to ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

A post-hoc analysis assessed micronutrient supplementation, including lutein and zeaxanthin, to determine if it slows progression of noncentral geographic atrophy. Share on Facebook. Opens in a ...

Laxmi Devisetty, MD, and Eva Kim, MD, look ahead at upcoming sessions focusing on geographic atrophy and refractive and ...

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

(RTTNews) - Annexon, Inc.(ANNX), on Thursday announced presentations highlighting the potential of its investigational drug ANX007 for the treatment of geographic atrophy or GA, a form of advanced ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™ ...

a multifunctional modifier gene therapy for the treatment of geographic atrophy or GA secondary to dry age-related macular degeneration or dAMD. The Phase 2 trial enrolled 51 subjects who were ...

Astellas Pharma seeks Japanese conditional approval of avacincaptad pegol intravitreal solution to treat geographic atrophy: Tokyo Thursday, February 6, 2025, 09:00 Hrs [IST] Aste ...